Nuvation Bio Inc SEC Filings

Nuvation Bio Inc. (NUVB) reported insider transactions by its Chief Medical Officer on Form 4. On 11/17/2025 and 11/19/2025, the officer exercised stock options to buy a total of 30,000 shares of Class A common stock at an exercise price of $1.87 per share and sold 30,000 shares in open-market transactions.

The sales included 15,000 shares on 11/17/2025 at $4.765 per share and 15,000 shares on 11/19/2025 at a weighted-average price of $5.1035 per share. After these transactions, the officer beneficially owned 18,000 shares of Class A common stock and held 470,000 stock options with a $1.87 exercise price expiring on 02/27/2034.

NUVB shareholder files notice to sell common shares under Rule 144. A holder of Class A common stock plans to sell 15,000 shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $76,552.50. These shares were acquired on 11/19/2025 by exercising options under a registered plan for cash and will be sold as freely tradable stock. The notice also reports a prior sale over the past three months of 15,000 Class A common shares on 11/17/2025 for gross proceeds of $71,475. The form includes a representation that the selling holder is not aware of any undisclosed material adverse information about NUVB’s operations.

NUVB Form 144 shows a planned insider sale of common stock. A holder has filed notice to sell 200,000 shares of Nuvation Bio common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,427,680.00. The shares are listed for sale on the NYSE with an approximate sale date of 11/19/2025. As of the filing, 342,833,433 shares of Nuvation Bio common stock were outstanding, which is a baseline figure for the company’s equity. The shares to be sold were acquired on 11/19/2025 by exercising stock options under a registered plan and paid for in cash.

Nuvation Bio Inc. released an updated corporate presentation and highlighted newly published positive Phase 2 data for its IDH1 inhibitor safusidenib in Japanese patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas. In an open-label study of 27 patients, safusidenib achieved an objective response rate of 44.4%, and median duration of response was not yet estimable because no progression had occurred. As of the data cut-off on March 10, 2023, median progression-free survival had not been reached, with 87.9% of patients progression free at 24 months and median follow-up of 28 months, suggesting durable disease control.

Adverse events were mostly mild to moderate; grade 3 or higher treatment-related events occurred in 18.5% of patients, with no grade 5 events and 11.1% discontinuations. A Good Clinical Practice noncompliance issue in adverse event collection was addressed through re-investigation and re-collection of safety data. Nuvation Bio is advancing the G203 global randomized study of safusidenib as maintenance therapy in high-grade and high-risk grade 2 IDH1-mutant gliomas, with a protocol amendment to finalize it as a global Phase 3 trial. The primary endpoint is progression-free survival by blinded central review, which the U.S. Food and Drug Administration has agreed could support full approval.

NUVB filed a Form 144 notice for a proposed sale of its Class A common stock. The filing covers a planned sale of 15,000 Class A common shares on the NYSE through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $71,475. These 15,000 shares were acquired on 11/17/2025 by exercising stock options under a registered plan, paid for in cash on the same date. The filing notes that 342,833,433 shares of Class A common stock were outstanding, providing context for the size of the planned sale.

Nuvation Bio (NUVB) reported Q3 2025 results. Total revenue was $13.1 million versus $0.7 million a year ago, driven by the first commercial sales of IBTROZI in the U.S. Product revenue was $7.7 million, and collaboration and license revenue was $5.4 million. Cost of revenue was $3.3 million, yielding gross profit of $9.8 million.

Operating expenses were $66.2 million (R&D $28.8 million; SG&A $37.4 million). Loss from operations was $56.4 million and net loss was $55.8 million ($0.16 per share). Weighted average shares outstanding were 342.4 million.

Liquidity remained significant with $549.0 million in cash, cash equivalents, and marketable securities as of September 30, 2025. During the nine months, the company received $150.0 million from a revenue interest financing agreement and $48.9 million in borrowings; operating cash outflow was $143.7 million. Total liabilities rose to $275.7 million, including $150.6 million related to the revenue interest financing and $47.1 million in long-term borrowings. IBTROZI began U.S. shipments in June 2025.

Nuvation Bio Inc. furnished a press release announcing its financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 to this Form 8-K and, along with the related information, is furnished rather than filed under the Exchange Act and Securities Act, except as specifically incorporated by reference. The company’s Class A Common Stock (NUVB) and Redeemable Warrants (NUVB.WS) are listed on the NYSE.

Nuvation Bio (NUVB) insider transaction: The Chief Scientific Officer executed a stock option exercise for 100,000 Class A shares at $1.74 (code M) on 10/27/2025 and sold 100,000 shares at a weighted-average price of $5.0246 (code S) pursuant to a Rule 10b5-1 plan dated June 24, 2024.

Following the transactions, non-derivative holdings were 0 shares. Derivative holdings included 298,935 stock options. The option grant referenced vests 25% on July 1, 2020, with the remainder in equal monthly installments over three years.

NUVB filed a Form 144 notice indicating a planned sale of 100,000 common shares. The filing lists an aggregate market value of $485,000 and identifies Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004) as the broker. The approximate date of sale is 10/27/2025, and the shares are listed on the NYSE.

The seller acquired the shares on 10/27/2025 through an exercise of stock options from the issuer, with cash as the form of payment. The filing also notes 342,272,722 shares outstanding.